Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 4
2023 3
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.
Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J, Dytfeld D, Angelucci E, Perrot A, Benjamin R, van de Donk NWCJ, Ocio EM, Scheid C, Gay F, Roeloffzen W, Rodriguez-Otero P, Broijl A, Potamianou A, Sakabedoyan C, Semerjian M, Keim S, Strulev V, Schecter JM, Vogel M, Wapenaar R, Nesheiwat T, San-Miguel J, Sonneveld P, Einsele H, Moreau P. Mateos MV, et al. Among authors: nesheiwat t. Leukemia. 2022 May;36(5):1371-1376. doi: 10.1038/s41375-022-01531-2. Epub 2022 Mar 24. Leukemia. 2022. PMID: 35332278 Free PMC article.
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk NWCJ, Martin T, Suvannasankha A, De Braganca KC, Corsale C, Schecter JM, Varsos H, Deraedt W, Wang L, Vogel M, Roccia T, Xu X, Mistry P, Zudaire E, Akram M, Nesheiwat T, Pacaud L, Avivi I, San-Miguel J. Cohen AD, et al. Among authors: nesheiwat t. Blood. 2023 Jan 19;141(3):219-230. doi: 10.1182/blood.2022015526. Blood. 2023. PMID: 36095849 Free PMC article.
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
Raghunandan S, Pauly M, Blum WG, Qayed M, Dhodapkar MV, Elkhalifa M, Watkins B, Schoettler M, Horwitz E, Parikh S, Chandrakasan S, Leung K, Bryson E, Deeb L, Kaufman JL, Worthington-White D, Alazraki A, Schecter JM, Madduri D, Jackson CC, Zudaire E, Taraseviciute-Morris A, Babich A, Nesheiwat T, Vogel M, Lendvai N, Pacaud L, Williams KM. Raghunandan S, et al. Among authors: nesheiwat t. J Immunother Cancer. 2023 May;11(5):e006684. doi: 10.1136/jitc-2023-006684. J Immunother Cancer. 2023. PMID: 37137553 Free PMC article.
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
Weisel K, Krishnan A, Schecter JM, Vogel M, Jackson CC, Deraedt W, Yeh TM, Banerjee A, Yalniz F, Nesheiwat T, Van Sanden S, Diels J, Valluri S, Usmani SZ, Berdeja JG, Jagannath S, Martin T. Weisel K, et al. Among authors: nesheiwat t. Clin Lymphoma Myeloma Leuk. 2022 Sep;22(9):690-701. doi: 10.1016/j.clml.2022.04.025. Epub 2022 May 23. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35764490 Free article. Clinical Trial.
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Mateos MV, Weisel K, Martin T, Berdeja JG, Jakubowiak A, Stewart AK, Jagannath S, Lin Y, Diels J, Ghilotti F, Thilakarathne P, Perualila NJ, Cabrieto J, Haefliger B, Erler-Yates N, Hague C, Jackson CC, Schecter JM, Strulev V, Nesheiwat T, Pacaud L, Einsele H, Moreau P. Mateos MV, et al. Among authors: nesheiwat t. Haematologica. 2023 Aug 1;108(8):2192-2204. doi: 10.3324/haematol.2022.280482. Haematologica. 2023. PMID: 36546453 Free PMC article.
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Costa LJ, Hari P, Berdeja JG, De Stefano V, Gay F, Hooper B, Bartlett M, Haltner A, Rosta E, Kumar S, Martin T, Mateos MV, Moreau P, Usmani SZ, Olyslager Y, Schecter JM, Roccia T, Garrett A, Lee S, Nesheiwat T, Pacaud L, Zhou C, Samjoo IA, Lin Y, Diels J, Valluri S, Weisel K. Costa LJ, et al. Among authors: nesheiwat t. Curr Med Res Opin. 2022 Oct;38(10):1759-1767. doi: 10.1080/03007995.2022.2100651. Epub 2022 Aug 10. Curr Med Res Opin. 2022. PMID: 35815818
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Weisel K, Martin T, Krishnan A, Jagannath S, Londhe A, Nair S, Diels J, Vogel M, Schecter JM, Banerjee A, Berdeja JG, Nesheiwat T, Garrett A, Qi K, Valluri S, Usmani SZ, Yong K. Weisel K, et al. Among authors: nesheiwat t. Clin Drug Investig. 2022 Jan;42(1):29-41. doi: 10.1007/s40261-021-01100-y. Epub 2021 Nov 25. Clin Drug Investig. 2022. PMID: 34822128 Free PMC article. Clinical Trial.
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry.
Merz M, Goldschmidt H, Hari P, Agha M, Diels J, Ghilotti F, Perualila NJ, Cabrieto J, Haefliger B, Sliwka H, Schecter JM, Jackson CC, Olyslager Y, Akram M, Nesheiwat T, Kellermann L, Jagannath S. Merz M, et al. Among authors: nesheiwat t. Cancers (Basel). 2021 Nov 29;13(23):5996. doi: 10.3390/cancers13235996. Cancers (Basel). 2021. PMID: 34885106 Free PMC article.